Alexander B. Olawaiye, MD, shares how relacorilant’s recent approval might change the treatment landscape for ovarian cancer.
Amram Kahn, MD, shares strategies for reconciling disparate clinical recommendations to optimize medication regimens for ...
A prospective survey study presented at the 2026 ASCO Annual Meeting highlighted the heterogeneity of patient experiences ...
"It's the first study to show a significant difference between all three covalent BTK inhibitors," says Daniel A. Ermann, MD.
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) may be prescribed to people with heart failure, chronic kidney disease, ...
As fireworks injuries and fires surge around July 4th, officials urge safer celebrations and greater public awareness nationwide.
To support physicians facing escalating economic pressures on independent practice, the AMA on June 11, 2026, launched an affinity program with Panacea Financial, a financial technology platform built ...
In a review of nearly 2,000 cases involving patients undergoing emergency surgery, factors independently associated with increased risk for ICU admission included advanced age, trauma-related ...
Hippocrates declared, “Let food be thy medicine and medicine be thy food.” Wise and enduring advice for promoting health and longevity, this phrase has become a defining message of modern preventive ...
Time for a heroic dose of humor! This week’s medical cartoon shows that even super‑speed can’t save the day in delayed care.
The following is a summary of “Quality evaluation of the usefulness of an emergency department fall risk assessment tool,” published in the February 2024 issue of Emergency Medicine by Ortenzio, et al ...
Tildrakizumab, an anti-IL-23 p19 monoclonal antibody, is a viable treatment option for patients with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results